Alvotech(US:ALVO) Globenewswireยท2025-06-02 13:15Company Overview - Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide [3] - The company aims to be a leader in the biosimilar space by delivering high-quality, cost-effective products and services through a fully integrated approach and broad in-house capabilities [3] - Alvotech has launched two biosimilars and has a development pipeline targeting autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [3] Strategic Partnerships - Alvotech has formed a network of strategic commercial partnerships to enhance its global reach and leverage local expertise in various markets, including the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [3] - Notable commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd, and Dr. Reddy's, among others, each covering unique products and territories [3] Upcoming Events - Alvotech will participate in the Jefferies Global Healthcare Conference 2025 in New York from June 3-5, 2025 [1] - Dr. Balaji Prasad, Chief Strategy Officer, will present recent business updates on June 5, 2025, from 10:30 am to 11:00 am EDT [1] - A live video webcast of the presentation will be available to the public, with a recording accessible for 90 days post-event [2]